Get the Stockscreener App
30.96
0.45%
-0.14
After Hours:
30.80
-0.16
-0.52%
Veracyte Inc stock is traded at $30.96, with a volume of 793.17K.
It is down -0.45% in the last 24 hours and down -23.33% over the past month.
See More
Previous Close:
$31.10
Open:
$32.045
24h Volume:
793.17K
Relative Volume:
0.96
Market Cap:
$3.29B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-41.28
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-6.07%
1M Performance:
-23.33%
6M Performance:
+1.78%
1Y Performance:
+38.71%
1-Day Range:
$30.63
$32.34
1-Week Range:
$30.09
$33.38
52-Week Range:
$18.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
30.96 | 3.29B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
512.65 | 193.40B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
204.96 | 146.49B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
119.85 | 34.19B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
412.40 | 33.54B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
185.42 | 32.69B | 15.41B | 1.37B | 2.11B | 7.50 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte’s chief commercial officer John Leite sells $234,629 in stock By Investing.com - Investing.com Canada
Veracyte’s chief commercial officer John Leite sells $234,629 in stock - Investing.com
Veracyte (VCYT) Surged on Reporting Strong Earnings - Insider Monkey
Veracyte Inc to Host Earnings Call - ACCESS Newswire
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality - Simply Wall St
29,779 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Proficio Capital Partners LLC - Defense World
Veracyte at Raymond James Conference: Strategic Expansion and Growth By Investing.com - Investing.com Australia
Insider Sell: Phillip Febbo Sells Shares of Veracyte Inc (VCYT) - GuruFocus.com
Veracyte at Raymond James Conference: Strategic Expansion and Growth - Investing.com
Principal Financial Group Inc. Has $1.29 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - Simply Wall St
Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Truist Financial Corp - Defense World
Veracyte's (NASDAQ:VCYT) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Veracyte (NASDAQ:VCYT) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
Veracyte (NASDAQ:VCYT) Given Buy Rating at Needham & Company LLC - MarketBeat
ARK Investment Management LLC Reduces Holdings in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte (NASDAQ:VCYT) Trading 9.9% Higher on Analyst Upgrade - MarketBeat
Guggenheim Reaffirms Buy Rating for Veracyte (NASDAQ:VCYT) - MarketBeat
Phocas Financial Corp. Reduces Stake in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte (NASDAQ:VCYT) Shares Gap Down Following Weak Earnings - MarketBeat
VERACYTE, INC. SEC 10-K Report - TradingView
Rhumbline Advisers Purchases 675 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
StockNews.com Downgrades Veracyte (NASDAQ:VCYT) to Hold - Defense World
Veracyte (NASDAQ:VCYT) Cut to "Hold" at StockNews.com - MarketBeat
Investor Network: Veracyte Inc to Host Earnings Call - ACCESS Newswire
Veracyte’s Strong Market Position and Growth Potential Drive Buy Rating - TipRanks
Ieq Capital LLC Acquires New Shares in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte (NASDAQ:VCYT) Earns Buy Rating from Needham & Company LLC - Defense World
Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Principal Securities Inc. Acquires 485 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
UBS Group Forecasts Strong Price Appreciation for Veracyte (NASDAQ:VCYT) Stock - Defense World
D.A. Davidson & CO. Buys Shares of 23,354 Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte Shares Surge Amid Financial Success and Challenges - TipRanks
Veracyte (NASDAQ:VCYT) Shares Gap Down on Disappointing Earnings - Defense World
Veracyte Inc. Reports Strong 2024 Earnings Amid Challenges - TipRanks
Needham maintains Veracyte stock Buy rating, $51 target By Investing.com - Investing.com Canada
A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts - Benzinga
Veracyte Enters Oversold Territory (VCYT) - Nasdaq
Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates - MSN
Veracyte, Inc. (NASDAQ:VCYT) Q4 2024 Earnings Call Transcript - MSN
Solid Growth, Soft Outlook: Why I’m Holding On Veracyte (NASDAQ:VCYT) - Seeking Alpha
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive - Benzinga
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat - MSN
Thyroid Cancer Diagnostics Market to Reach USD 4.81 Billion by 2032, Growing at 5.65% CAGR – SNS Insider - GlobeNewswire
Earnings call transcript: Veracyte Q4 2024 earnings beat but stock dips By Investing.com - Investing.com South Africa
Needham maintains Veracyte stock Buy rating, $51 target - Investing.com India
Veracyte Inc (VCYT) Q4 2024 Earnings Call Highlights: Record Rev - GuruFocus.com
Veracyte Inc (VCYT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Veracyte Inc (VCYT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Veracyte: Q4 Earnings Snapshot - The Washington Post
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.20%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):